Key points from article :
New therapy is a combination of dabrafenib and trametinib drugs.
Clinical trial found a lower risk of the cancer recurring in some patients.
A gene mutation (BRAF) is found in approximately half of melanoma cases.
At present, patients have to hope their cancer will not return after surgery.
